Kempen & Co acted as Joint Bookrunner in Oncopeptides’ SEK 1.11bn capital increase
Oncopeptides is a pharmaceutical company that develops pharmaceuticals for the treatment of cancer. Its lead product candidate is PEPAXTO (also known as melflufen), a novel peptide conjugated alkylator for the treatment of hematological cancer multiple myeloma, recently got approved by the FDA for commercial use in the US. Oncopeptides is developing a host of different drug candidates across a variety of indications.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: